Clinical trials: Injection Site, open to volunteers
Advanced, Metastatic Breast Cancer
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara® (oral tablet), both given together with ribociclib, for the first-line treatment of postmenopausal women with…
- Trial name
- SIE-3 (NCT07340658)
- Volunteers
- 300 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Rectal Cancer, Advanced Stage Colorectal Cancer
SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
This is a multicenter, cohort, prospective study to evaluate the efficacy and safety of Adebrelimab combined with radiotherapy and chemotherapy as preoperative neoadjuvant therapy for patients with locally advanced rectal cancer.
- Conditions
- Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy
- Trial name
- NCT07284992
- Testing
- short-term radiotherapy combined with Adebrelimab and capox, long-term radiotherapy combined with Adebrelimab and capox
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Shandong Provincial Hospital
HRD-negative Epithelial Ovarian Cancer
A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer
This is a single-center, open-label, dose-escalation, multiple-dose investigator-initiated exploratory study designed to evaluate the safety, tolerability and preliminary efficacy of tumor neoantigen-pulsed autologous dendritic…
- Trial name
- YS247 (NCT07455071)
- Testing
- Tumor Neoantigen-Sensitized Autologous Dendritic Cell Injection (YS247)
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital
Esophageal Cancer
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1…
- Trial name
- NCT07367516
- Testing
- TQB6411 Injection
- Where
- 30 sites in China
- Volunteers
- 105 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Melanoma, Non Small Cell Lung Cancer
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Cervical Carcinoma
- Trial name
- NCT05366478
- Testing
- Autologous tumor infiltrating lymphocytes (TILs)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Gynecological Malignant Tumor, Solid Tumor
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
- Trial name
- NCT05803018
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Borderline Resectable/Unresectable Pancreatic Cancer, Non Metastatic Pancreatic Cancer
Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer
By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.
- Trial name
- NCT07539155
- Testing
- Intratumoral MMR Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Bladder Cancer (BC)
Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC)
Recombinant oncolytic adenovirus injection (KD01) is an oncolytic virus product. Its main component is a conditionally replicative recombinant human type 5 adenovirus, where part of the E3 region has been replaced with the gene…
- Trial name
- NCT07359235
- Testing
- KD01(the recombinant oncolytic adenovirus)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tongji Hospital
Gastrointestinal Tumors, Solid Tumor
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in…
- Trial name
- NCT06755242
- Testing
- GNC-077
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Cancer-related Fatigue
PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe…
- Trial name
- NCT05440227
- Testing
- PG2 Lyo. Injection 500mg
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- PhytoHealth Corporation
HER2 + Breast Cancer
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.
- Trial name
- NCT07294534
- Testing
- HLX87+HX22, HLX87 + Pertuzumab, TCbHP
- Volunteers
- 817 people
- Sponsor
- Shanghai Henlius Biotech
Pancreatic Cancer
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
This is a single-arm, open-label clinical study to evaluate the safety, tolerability and preliminary efficacy of IX001 TCR-T injection in advanced pancreatic cancer patients with KRAS G12V mutation.
- Trial name
- IX001 TCR-T (NCT06898385)
- Testing
- IX001 TCR-T injection, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 5 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles.
- Trial name
- NCT07542379
- Testing
- 177Lu-FC516
- Where
- China
- Volunteers
- 13 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Non-Small Cell Lung Cancer
A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer
This is a multicenter, open-label, Phase 1 clinical study to evaluate the efficacy and safety of HS-20093 combination therapy in subjects with advanced or metastatic non-small cell lung cancer without actionable genomic…
- Trial name
- NCT07899086
- Testing
- HS-20093, Ivonescimab, Chemotherapy
- Volunteers
- 102 people
- Sponsor
- Hansoh BioMedical R&D Company
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
- Trial name
- NCT06700070
- Testing
- PBA-0111
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Pure Biologics S.A.
Non-small Cell Lung Cancer (NSCLC)
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with NSCLC.
- Trial name
- NCT06754930
- Testing
- SHR-1826, SHR-1316, SHR-9839
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-hodgkin's Lymphoma
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Phase I main objectives: To observe the safety and preliminary efficacy of GNC-035 in patients with relapsed/refractory non-Hodgkin lymphoma and other hematological malignancies, to determine the DLT and MTD, or MAD, and to…
- Trial name
- NCT06066203
- Testing
- GNC-035
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with…
- Trial name
- NCT06892431
- Testing
- Mitoxantrone Hydrochloride Liposome, JMT101 injection, Capecitabine
- Volunteers
- 150 people
- Sponsor
- Shanghai JMT-Bio Inc.
Melanoma (Skin), Triple-Negative Breast Cancer
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to…
- Conditions
- Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma
- Trial name
- NCT05492682
- Testing
- PeptiCRAd-1, Cyclophosphamide, Pembrolizumab
- Where
- 7 sites in Germany, Italy
- Volunteers
- 15 people
- Sponsor
- Valo Therapeutics Oy
Advanced Solid Tumor, Lung Squamous Cell Carcinoma
JMT106 Injection in the Treatment of Advanced Solid Tumors
This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT07275073
- Testing
- JMT106 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai JMT-Bio Inc.